Companies › Beijing Scitech-Mq Pharmaceuticals
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ST-1898 Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI | VEGFR2, MET, AXL, PDGFRA, RET | Phase 2 | Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell Carcinoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06359860 | ST-1898 | Phase 1 | Unresectable or Metastatic Melanoma | Oncology | Dec 2026 |
| NCT06127238 | ST-1898 | Phase 1 | Advanced Renal Cell Carcinoma | Oncology | Feb 2027 |
| NCT06359847 | ST-1898 | Phase 2 | Differentiated Thyroid Carcinoma | Oncology | Dec 2027 |
Apollomics Abion Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.